


**Product Name** : TR-107  
**Cat. No.** : PC-49211  
**CAS No.** : 2485052-87-5  
**Molecular Formula** : C<sub>22</sub>H<sub>19</sub>ClN<sub>4</sub>O  
**Molecular Weight** : 390.871  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



## Biological Activity

TR-107 (TR107) is a highly potent, selective and orally bioavailable small-molecule activator of the **mitochondrial protease ClpP** with EC<sub>50</sub> of 140 nM, binds to purified ClpP with K<sub>d</sub> value of 180 nM in surface plasmon resonance (SPR) measurement.

TR-107 dose-dependent increases ClpP activity, inhibits breast cancer cell MDA-MB-231 and SUM159 growth (IC<sub>50</sub>=23 and 12 nM) in a ClpP-dependent manner, without a significant increase in apoptosis.

TR-107 showed significantly enhanced potency of cell growth inhibition in the MDA-MB-231 and SUM159 cell models compared with ONC201 and ONC206.

TR-107 (100 nM, 6-24 h) induces time- and dose-dependent reduction of multiple mitochondrial proteins (TUFM and TFAM, aconitase (ACO2) and isocitrate dehydrogenase (IDH2), and succinate dehydrogenase A (SDHA) and complex I subunit NDUFS3).

TR-107 reduces mitochondrial metabolic functions and inhibits OXPHOS in MDA-MB-231 cells.

TR-107 (4-8 mg/kg, p.o.) prevents tumor growth in MDA-MB-231 xenograft model.

## References

Fennell EMJ, et al. *Pharmacol Res Perspect.* 2022 Aug;10(4):e00993.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com